Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

merger acquisition M&A business

Boston Scientific finalizes Bolt Medical acquisition as FDA clears company’s IVL technology

Boston Scientific hopes to officially launch its new IVL system in the first half of 2026.

Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, and a clinical professor of medicine at Wake Forest University School of Medicine, offers what he saw as the main takeaway messages in the ACC 2025 late breaking trials.

Key takeaways from ACC.25: Advances in cardiovascular science

Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
 

Philippe Généreux, MD, presenting late-breaking clinical research on TAVR at ACC.25

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.

Sergio Raposeiras-Roubin, MD, presenting new data on TAVR and dapagliflozin at ACC.25 in Chicago

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.

NCH Rooney Heart Center is building a comprehensive program in Florida.

Bringing state-of-the-art healthcare to Florida heart patients

Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far. 

Thumbnail

Cardiologists make case against routine interventions for asymptomatic severe AS

Aortic valve replacement is likely inevitable for patients with asymptomatic severe aortic stenosis. Immediately performing TAVR or SAVR, however, may not always be the answer.

An FDA panel will discuss its recommendations related to Abbott's TriClip G4 transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation.

First comprehensive T-TEER resource examines best practices for tricuspid valve repair

"We wanted to ensure that every interventionalist, regardless of location or resources, has access to the best information possible," one co-author said. 

Michael Reardon at ACC.25 presenting data on low-risk TAVR and SAVR patients

So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients

Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.